Mer­ck drops out of a $125M KRAS al­liance with Mod­er­na, tak­ing a step away from the Covid-19 star

Four years ago, Mer­ck’s Roger Perl­mut­ter lined up to pay Mod­er­na an ex­tra $125 mil­lion for pre­ferred eq­ui­ty to gain rights to its ear­ly stage KRAS pro­gram for mR­NA-5671. But now that deal is over.

Mod­er­na not­ed the tran­si­tion in its Q4 re­port to­day, not­ing that it re­gained all rights to the ther­a­py and is now con­sid­er­ing “next steps.”  The com­pa­ny added:

The Phase 1 open-la­bel, mul­ti-cen­ter study to eval­u­ate the safe­ty and tol­er­a­bil­i­ty of mR­NA-5671 both as a monother­a­py and in com­bi­na­tion with pem­brolizum­ab (Keytru­da), led by Mer­ck, is on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER